{"id":17793,"date":"2026-06-09T01:48:00","date_gmt":"2026-06-08T23:48:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=7aeb5bdca5e67da2fc89dd77b6a55e52"},"modified":"2026-06-09T01:48:00","modified_gmt":"2026-06-08T23:48:00","slug":"medp-deadline-alert-faruqi-faruqi-llp-reminds-medpace-medp-investors-of-securities-class-action-deadline-on-june-8-2026","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=17793","title":{"rendered":"MEDP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026"},"content":{"rendered":"

\nFaruqi & Faruqi, LLP Securities Litigation Partner <\/b>James (Josh) Wilson<\/b><\/a> Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options<\/b><\/p><\/a><\/a><\/a><\/a>

\nIf you purchased or acquired securities in <\/b>Medpace<\/b><\/a> between April 22, 2025 and February 9, 2026 <\/b>and would like to discuss your legal rights, call<\/span> Faruqi & Faruqi partner Josh Wilson directly <\/b>at 877-247-4292 <\/b>or 212-983-9330 (Ext. 1310)<\/b>.<\/p>

\n[You may also click here for additional information]<\/a><\/b><\/p>

NEW YORK--(BUSINESS WIRE)--$MEDP<\/a> #ClassAction<\/a>--Faruqi & Faruqi, LLP<\/a>, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. (\u201cMedpace\u201d or the \u201cCompany\u201d) (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline<\/b> to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.<\/p>

\nFaruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com<\/a>.<\/p>

\nAccording to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and\/or concealing material adverse facts concerning the true state of Medpace's backlog cancellation rate. Defendants continuously touted \"well behaved\" cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio.<\/p>

\nOn February 9, 2026, Medpace issued a press release announcing the Company's fourth quarter 2025 book-to-bill ratio of 1.04, well below the guidance of 1. 15. Following this news, the price of Medpace's common stock declined dramatically. From a closing market price of $530.35 per share on February 9, 2026, Medpace's common stock price fell to $446.05 per share on February 10, 2026, a decline of more than 15.9%.<\/p>

\nThe court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.<\/p>

\nFaruqi & Faruqi, LLP also encourages anyone with information regarding Medpace\u2019s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.<\/p>

\nTo learn more about the Medpace<\/b> class action, go to www.faruqilaw.com\/MEDP<\/b><\/a> or call<\/b><\/span> Faruqi & Faruqi partner Josh Wilson directly <\/b>at 877-247-4292 <\/b>or 212-983-9330 (Ext. 1310)<\/b>.<\/p>

\nFollow us for updates on LinkedIn<\/a>, on X<\/a>, or on Facebook<\/a>.<\/p>

\nAttorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com<\/a>). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.<\/p> Contacts<\/b>

\nFaruqi & Faruqi, LLP\nJosh Wilson\n877-247-4292 or 212-983-9330 (Ext. 1310)<\/p>","protected":false},"excerpt":{"rendered":"

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options
\nIf you purchased or acquired securities in Medpace between April 22, 2025 a…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-17793","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17793"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17793\/revisions"}],"predecessor-version":[{"id":17794,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17793\/revisions\/17794"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}